A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study

BACKGROUND: Activation of the mammalian target of rapamycin (mTOR) pathway is observed in neurofibromatosis type 1 (NF1) associated low-grade gliomas (LGGs), but agents that inhibit this pathway, including mTOR inhibitors, have not been studied in this population. We evaluate the efficacy of the ora...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Ullrich, Nicole J, Prabhu, Sanjay P, Reddy, Alyssa T, Fisher, Michael J, Packer, Roger, Goldman, Stewart, Robison, Nathan J, Gutmann, David H, Viskochil, David H, Allen, Jeffrey C, Korf, Bruce, Cantor, Alan, Cutter, Gary, Thomas, Coretta, Perentesis, John P, Mizuno, Tomoyuki, Vinks, Alexander A, Manley, Peter E, Chi, Susan N, Kieran, Mark W
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Pediatric Neuro-Oncology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7566451/
https://ncbi.nlm.nih.gov/pubmed/32236425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa071
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items